



Ironwood Pharmaceuticals, Inc.
Investor Relations Department
301 Binney Street, 2nd floor
Cambridge, MA 02142
United States

Visit IR website [↗](#)
Sign-up for email alerts [↗](#)

NASDAQ: IRWD ¹

Last Trade:	15.04
Trade Time:	4:00 PM ET Oct 18, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	12.48 - 19.94
Volume	N/A
Market Cap. (\$M)	2,031.453
Shares Out (M)	135.070

¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

At Ironwood, we're focused on delivering differentiated medicines to patients. If we do this efficiently and effectively, we hope to generate outstanding returns for our shareholders, inspiring their continued support so that we can create more medicines and build an enduring pharmaceutical company. These are not small goals, but we believe they represent the best way to maximize long-term value for both patients and shareholders.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Oct 16, 2017

[Ironwood Pharmaceuticals Presenting Linaclotide Data at the World Congress of Gastroenterology at ACG 2017](#)

Sep 6, 2017

[Ironwood Pharmaceuticals Announces Leadership Change](#)

Aug 31, 2017

[Ironwood Pharmaceuticals to Present at Upcoming September Investor Conferences](#)

Aug 21, 2017

[Ironwood Pharmaceuticals Announces FDA Approval of DUZALLO® \(lesinurad and allopurinol\) for the Treatment of Hyperuricemia in Patients with Uncontrolled Gout](#)

Aug 3, 2017

[Ironwood Pharmaceuticals Provides Second Quarter 2017 Investor Update](#)

Events [\[View all \]](#)

There are no events to display at this time. Please check back later.

Financials [\[View all \]](#)

[Second Quarter Financial Results](#)

Feb 22, 2017

[Annual Report \(10-K\)](#)

Apr 18, 2017

[Definitive Proxy Statement](#)

Aug 3, 2017

[Quarterly Report \(10-Q\)](#)

May 8, 2017

[Quarterly Report \(10-Q\)](#)

Nov 7, 2016

[Quarterly Report \(10-Q\)](#)